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Plasmodium vivax radical cure requires the use of primaquine (PQ), a drug that induces haemolysis in glucose-
6-phosphate dehydrogenase deficient (G6PDd) individuals, which further hampers malaria control efforts. The aim 
of this work was to study the G6PDd prevalence and variants in Latin America (LA) and the Caribbean region. A sys-
tematic search of the published literature was undertaken in August 2013. Bibliographies of manuscripts were also 
searched and additional references were identified. Low prevalence rates of G6PDd were documented in Argentina, 
Bolivia, Mexico, Peru and Uruguay, but studies from Curaçao, Ecuador, Jamaica, Saint Lucia, Suriname and Trini-
dad, as well as some surveys carried out in areas of Brazil, Colombia and Cuba, have shown a high prevalence (> 
10%) of G6PDd. The G6PD A-202A mutation was the variant most broadly distributed across LA and was identified in 
81.1% of the deficient individuals surveyed. G6PDd is a frequent phenomenon in LA, although certain Amerindian 
populations may not be affected, suggesting that PQ could be safely used in these specific populations. Population-
wide use of PQ as part of malaria elimination strategies in LA cannot be supported unless a rapid, accurate and 
field-deployable G6PDd diagnostic test is made available.
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Glucose-6-phosphate dehydrogenase (G6PD) is a cy-
toplasmic enzyme. The major function of G6PD is the 
prevention of oxidative damage to cells by promoting 
detoxification of free radicals. This metabolic pathway 
involves the production of nicotinamide adenine dinu-
cleotide phosphate (NADPH), which participates in the 
glutathione (GSH) cycle, protecting the cell against hy-
drogen peroxide-induced damage and assuring an oxida-
tive balance profile within the cell (Cappellini & Fiorelli 
2008). The G6PD gene presents an X-linked pattern 
(Beutler 1994), where hemizygous males and homozy-
gous females are deficient and heterozygous females 
may or may not be deficient because of mosaicism. 
Despite the majority of G6PD deficient (G6PDd) indi-
viduals being asymptomatic, some present haemolytic 
incidents that may be triggered by intrinsic or extrinsic 
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stressors, e.g., diabetic ketoacidosis, drugs, pathogens 
or types of food, causing syndromes such as acute hae-
molytic anaemia (AHA), neonatal jaundice (NNJ) and 
congenital non-spherocytic haemolytic anaemia, with 
the resulting manifestations depending on the amount of 
oxidative stress experienced in the cells and the levels of 
enzyme activity (Mason et al. 2007).
G6PDd is found worldwide with varying frequen-
cies depending on the region and ethnic group. The 
overall G6PDd allele frequency across malaria endemic 
countries is estimated to be 8%, corresponding to ap-
proximately 220 million males and 133 million females 
(Howes et al. 2012). Variable enzyme activity levels have 
been measured among deficient individuals based on the 
diversity of mutations. The World Health Organization 
(WHO) has classifies G6PDd according to enzyme ac-
tivity, ranging from ≤ 1% to over 150%, classes I-V, re-
spectively, in which classes I, II and III are considered 
at risk for haemolytic events (WHO 1989). The highest 
G6PDd prevalence has been found to occur in sub-Saha-
ran Africa and the Arabian Peninsula (Howes et al. 2012). 
Recent data found 186 known G6PD genotypic variants, 
most of them resulting in phenotypes that are asymp-
tomatic until exposed to haemolytic triggers (Minucci 
et al. 2012). These G6PD variants are heterogeneously 
spread among different countries, presenting distinct 
region-specific distributions (Howes et al. 2013), which 
could be related to specific routes of human migration. 
Among all the known deficiencies, the G6PD A- and the 
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G6PD Mediterranean variants have been reported to be 
detected more frequently in certain populations and are 
the variants primarily responsible for the occurrence of 
haemolytic events (Frank 2005). The G6PD A- variant 
is the most predominant allele in the African continent, 
whereas the G6PD Mediterranean allele is more frequent 
in Western Asia (Howes et al. 2013).
Malaria in humans is predominantly caused by two 
Plasmodia species, Plasmodium falciparum and Plasmo-
dium vivax and is estimated to be spread over more than 
90 countries, putting nearly 3.3 billion people at risk of 
disease (Guerra et al. 2010, WHO 2012a). The prevalence 
of G6PDd across countries was found to have a good cor-
relation with those where, historically, malaria transmis-
sion has occurred (Howes et al. 2012). The explanation 
for this association has been that G6PDd is associated 
with protection against P. falciparum (Mockenhaupt et al. 
2003, Clark et al. 2009) and P. vivax infections (Leslie 
et al. 2010, Santana et al. 2013). The mechanism confer-
ring resistance in G6PDd subjects may be related to an 
impaired antioxidant defence in ring-stage parasitised red 
cells, which could lead to membrane damage, triggering 
increased removal of infected cells by phagocytosis before 
parasite maturation to the trophozoite and schizont stages 
(Ruwende et al. 1995). G6PDd is also thought to be a pro-
tection factor against severe manifestations of malaria, al-
though studies regarding which individuals, hemizygous 
males or heterozygous females, may be protected present 
discrepancies (Ruwende et al. 1995, Guindo et al. 2007).
In a context where the international community has 
committed to a renewed malaria eradication agenda 
(malERA 2011), many countries have been planning to 
reduce transmission or eliminate malaria, making the 
development and deployment of cost-effective strategies 
extremely necessary (Das & Horton 2010). Primaquine 
(PQ), an 8-aminoquinoline, is currently the only Food 
and Drug Administration approved drug recommended 
to treat hepatic stages of the P. vivax. The WHO rec-
ommends that PQ should be used in radical cure for P. 
vivax malaria (0.5 mg/kg/d for 14 days) (WHO 2010) or 
as a gametocytocidal agent in uncomplicated P. falci-
parum infections (0.25 mg/kg in a single dose) (WHO 
2012b). The use of PQ or other 8-aminoquinolines such 
as tafenoquine (undergoing Phase III clinical trials) in 
G6PDd individuals presents serious risks, as these com-
pounds may induce life-threatening haemolytic events, 
the intensities of which depends on the individual’s en-
zyme activity profile (Llanos-Cuentas et al. 2013, von 
Seidlein et al. 2013). The WHO recommends that in 
mild-to-moderate G6PDd, PQ (0.75 mg base/kg) should 
be given once a week over eight weeks, while in severe 
G6PDd patients, PQ is contraindicated (WHO 2010).
Geographically, P. vivax is more widely distributed 
than P. falciparum, with the former species having a po-
tential to cause morbidity and mortality amongst the 2.85 
billion people living at risk of infection, most of them 
in Central and Southeast Asia and Latin America (LA) 
(Guerra et al. 2010). In LA and the Caribbean, only Chile, 
Uruguay, Cuba, Bahamas, Jamaica and other small coun-
tries in the Caribbean are now considered malaria-free, 
while Mexico, Haiti, Costa Rica, El Salvador, Panama, 
Argentina and Paraguay have been classified as malaria-
eliminating countries. The remaining countries are still 
in the phase of controlling transmission (WHO 2012a). 
Predominance of P. vivax malaria in these countries is es-
pecially relevant given that radical cure requires the use of 
PQ, implying a risk of haemolysis and its adverse conse-
quences in G6PDd individuals (Beutler & Duparc 2007). 
The public health consequences of this condition deserve 
special attention because of the impossibility of using PQ 
in regions where there is a high prevalence of this deficien-
cy, further hampering transmission control efforts for this 
parasite species (White 2008, Baird & Surjadjaja 2011). 
Despite the clinical and epidemiological significance of 
the interaction between G6PDd and malaria, the preva-
lence of G6PDd and the extent of its clinical consequences 
have not been properly measured in LA populations.
In Brazil and other LA countries facing malaria as 
a public health problem, the treatment recommendation 
for P. vivax includes a full-course of PQ with no rou-
tine G6PDd screening. This short-sighted policy leads 
to the prescription of potentially haemolytic drugs, put-
ting G6PDd individuals at risk of serious complications 
(Lacerda et al. 2012b, Monteiro et al. 2014). We therefore 
reviewed the existing literature to estimate the preva-
lence of G6PDd in LA and to identify the most frequent 
variants that affect this population, highlighting areas 
where more research is necessary in the region.
MATERIALS AND METHODS
A systematic review was performed to analyse the 
available published data on G6PDd prevalence, pheno-
types and mutations in LA and the Caribbean. A broad 
free text search was made using a previously published 
search strategy (Monteiro et al. 2014). Potentially relevant 
papers in all languages were accessed from MEDLINE 
and LILACS for a review of the full texts. Additional ar-
ticles were obtained through citation tracking of reviews/
opinion articles and original papers. To identify relevant 
papers, two independent reviewers examined titles, ab-
stracts and full texts of the retrieved studies. Existing da-
tabases (Arends 1966, Fonseca et al. 2005, Howes et al. 
2012, 2013) were reviewed for any additional sources.
For G6PDd prevalence analysis, results of phenotyp-
ing tests from surveys in males were used. Potentially 
biased samples, including malaria patients, ethnically 
selected samples, individuals with a previous history of 
haemolytic anaemia, new-borns presenting jaundice and 
surveys based only on the search of specific genotypes 
were excluded because they tend to underestimate the 
real G6PDd prevalence (Howes et al. 2012). LA or Ca-
ribbean population migrants living in other continents 
were also excluded. Only surveys with precise informa-
tion of the study location were included. Data on loca-
tion of the study (country and locality), number of people 
tested, sex, number of G6PDd subjects, ethnicity, G6PD 
phenotypes/mutations found, relative prevalence of each 
variant and authorship information were extracted di-
rectly from the full length articles to structured Tables 
and Figures containing all the descriptive variables.
For G6PDd variant analysis, two types of studies 
were included: (i) representative community surveys on 
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G6PDd prevalence assessed by gel electrophoresis and/or 
genotyping methods and (ii) non-representative surveys, 
including all types of studies and populations. Thus, to 
build a G6PDd database of the variant diversity in LA 
and the Caribbean, both types of papers were included. 
Classification of the variants was made according to a 
review published previously (Minucci et al. 2012) and 
according to information given by the original articles.
A map was created with the software ArcMap 10.1 in 
ArcGIS 10.1 (ESRI, USA) using estimates of the crude 
average prevalence for males. Separate male analysis and 
estimates for the map values were performed because phe-
notypic expression is more reliable, thus rendering male 
estimates more suitable for cross-locality comparisons 
(Howes et al. 2012). Spatial interpolation of G6PD preva-
lence was mapped using 70 representative community 
surveys corresponding to 103 study sites where males had 
been sampled. Duplicate studies performed at the same 
locations were excluded and the study with the bigger 
sample size was retained. Several different interpolation 
methods were tried, including ordinary kriging, Kernel 
Interpolation with Barriers and Inverse Distance Weight-
ing (IDW). The latter was selected as it produces a contour 
surface that best represents broad zones where different 
G6PDd values may be predicted. IDW is a technique that 
determines cell values using a linearly weighted combina-
tion of a set of sample points. The weight is a function of 
inverse distance and the method assumes that the variable 
being mapped decreases in influence with distance from 
its sampled location (ArcMap 10.1 documentation). For 
this analysis, the output cell size was set to 0.33, a power 
value of 2 was used, the search neighbourhood was set to 
smooth circular with a 30.15 radius and a smoothing fac-
tor of 0.2 was used. The sample size was used as a weight 
variable. No features were used as barriers.
RESULTS AND DISCUSSION
The MEDLINE search generated 487 papers and the 
LILACS search generated 140 papers. After assessing the 
inclusion criteria, 70 original papers with representative 
community surveys on G6PDd prevalence in males from 
18 LA and Caribbean countries were found (Supplemen-
tary data). This systematic review also revealed 24 publi-
cations regarding G6PDd prevalence among Amerindian 
populations (16 publications from the original search and 
8 from after reading these primary references).
Moreover, 71 appropriate original papers regarding 
G6PD variant characterisation were retrieved. Thirty-
two additional articles were obtained through citation 
tracking of reviews/opinion articles and original papers. 
Of these 103 articles, 41 reported data from represen-
tative community surveys with G6PDd typing in males 
(28 using gel electrophoresis phenotyping and 13 using 
genotyping methods) (Supplementary data).
Prevalence estimates of G6PDd in LA and Carib-
bean - Overall numbers of individuals sampled were 
63,716 males and 12,868 females (Table I). Consider-
ing only malaria endemic countries, 53,399 males and 
10,079 females were tested. Brazil was the country with 
the largest number of males tested (n = 28,671; 53.7% 
of the male population tested in malaria endemic coun-
tries), followed by Mexico (n = 13,126; 24.6%). Low 
prevalence rates were recorded from Argentina, Bolivia, 
Mexico, Peru and Uruguay. Studies performed in Cura-
çao, Ecuador, Jamaica, Saint Lucia, Suriname and Trini-
dad, as well as some surveys carried out in areas of Bra-
zil, Colombia and Cuba, have shown a high prevalence 
(> 10%) of G6PDd. Studies were unevenly distributed, 
with some malaria endemic countries, including Belize, 
Guatemala, Nicaragua, Panama, Guyana, French Gui-
ana and Paraguay, not contributing any data.
Mapping showed large swathes in LA and Caribbean 
countries where G6PDd was predicted to have preva-
lence ≤ 2%, namely in Mexico, Guatemala, Peru, Bo-
livia, Uruguay, Chile and Argentina (Fig. 1). Relative to 
these countries, prevalence was higher in the Caribbean 
islands, French Guiana, Suriname, Guyana, northwest-
ern Venezuela and Pacific coastal regions of Colombia 
and Ecuador, where the majority of the estimated areas 
of prevalence above 10% were located. In the Amazon 
Region, prevalence estimates ranged from 4% in the 
southern areas to 10% in the Guiana borders. Prevalence 
in the northern Amazonian area is most likely overesti-
mated due to the high G6PDd prevalence in Guyana and 
Suriname in the mapping model.
This map presents estimates of sub-national varia-
tions of G6PDd prevalence across LA and Caribbean 
countries. Recently, a global map presenting data at sub-
national levels using the same inclusion and exclusion 
criteria for retrieving articles was published (Howes et 
al. 2012). These authors mapped LA and Caribbean G6P-
Dd based on 34 published articles. In the current review, 
by searching in LA specific databases and not applying 
any language restrictions, we were able to increase the 
number of usable publications to 70 articles. This higher 
sensitivity (great number of literature published region-
ally retrieved from LILACS database) most likely adds 
Fig. 1: map of estimated prevalence of glucose-6-phosphate dehydro-
genase deficient across Latin America and the Caribbean countries.
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TABLE I
Summary of the results of surveys on glucose-6-phosphate dehydrogenase  


















Argentina 4,437 0.3-0.5 - - 4,642 1.1
Bolivia 335 0.7-1.5 200 0 - -
Brazil 28,671 0-12.9 6,709 0-13.6 9,801 1.1-13.3
Colombia 988 1.4-15.4 - - 611 3.1-12.7
Costa Rica 1,371 0.4-12.6 1,683 0-7.8 1,628 0.4-5.4
Cuba 7,957 0.6-16.1 1,813 0.7-10.2 500 3.6
Curaçao 573 14 213 10.3 - -
El Salvador 778 2.4 416 6 370 0.5
Ecuador 1,173 9.3-12.8 - - - -
Jamaica 976 13.5-22.6 524 4.1-28.3 - -
Mexico 13,126 0-12.7 488 0-0.9 2,464 0-0.6
Peru 640 0-0.7 - - - -
Puerto Rico 56 5.4 143 2.8 - -
Saint Lucia 427 14.8 - - - -
Suriname 1,507 3.2-20.2 422 1.4 - -
Trinidad 328 13.4 - - - -
Uruguay - - 96 0 144 2.1
Venezuela 373 0-3.5 161 1.8-2.9 112 0
Total 63,716 0-22.6 12,868 0-28.3 20,272 0-13.3
a: from studies conducted with male and female individuals without gender-specific prevalence.
more accuracy in the spatial distribution of G6PDd in 
this continent. The geographic patterns presented here 
corroborate the findings of a previous study by Howes 
et al. (2012), which showed lower G6PDd frequencies in 
Mexico, Argentina, Bolivia and Peru. However, a higher 
G6PDd prevalence was found in the Caribbean islands, 
Guianas, Pacific coastal regions of Colombia and Ecuador 
and part of the Brazilian Atlantic Coast compared to the 
previous study. These regions coincide with the areas that 
received the greatest contribution of African immigrants, 
particularly as part of the slave trade (Franco 1979).
G6PDd variants in LA and Caribbean - LA stud-
ies concerning the characterisation of the G6PDd were 
mostly conducted using gel electrophoresis and mainly 
carried out before 1990. As shown in Fig. 2A, the results 
from biochemical characterisations performed after rep-
resentative community surveys on G6PDd prevalence 
revealed a broad geographic range of the African vari-
ant, which was recorded in 28 studies carried out in nine 
countries. Among 10,385 males tested in these studies, 
518 G6PDd individuals were identified and further typed 
as carriers of the African (463 males; 89.4%), Mediter-
ranean (41 males in 5 countries; 7.9%) or Seattle (1 male 
from Brazil; 0.2%) variants. Samples from 13 individu-
als were not conclusively characterised by gel electro-
phoresis. In addition to G6PDd variant characterisation 
using samples from community surveys, 35 additional 
biochemical variants were recorded and published as 
case reports (see database presented in Table II). These 
publications are generally descriptions of putative new 
G6PD variants in people presenting non-spherocytic 
anaemia or episodes of haemolysis.
Fig. 2B presents the results from characterisation 
of G6PD variants at the DNA level performed after 13 
community surveys on G6PDd prevalence from five 
countries. It showed that the G6PD encoded by the 
G6PD A-202A mutation is the most broadly distributed 
across LA and was identified in 81.1% of deficient indi-
viduals surveyed in the continent (687 of 847 total G6P-
Dd males surveyed). Other variants identified included 
G6PD A-968G (59 males; 7%), G6PD Mediterranean (19; 
2.2%), Santamaria (16; 1.9%), Seattle (16; 1.9%), Belém 
(3; 0.3%) and Chatham (2; 0.2%). Some other rare vari-
ants were recorded from Belém, in the Eastern Brazil-
ian Amazon (Hamel et al. 2002). Thirty-four individuals 
were not typed because some investigations do not per-
form total G6PD gene sequencing, thus indicating that 
new mutations possibly exist in this continent. In Campi-
nas, Brazil, nine out of the 74 deficient individuals were 
found to carry the G6PD A-202A mutation (12.2%) (Saad 
et al. 1995). A community screening survey showed 
an estimated prevalence of 6% for the G6PD A-202A in 
Acrelândia, Brazil (Cardoso et al. 2012).
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Fig. 2: spatial distribution of glucose-6-phosphate dehydrogenase deficient variants characterised by gel electrophoresis (A) and molecular 
analysis (B) in Latin American and Caribbean community-level studies. Sample size is reflected in the size of the pie charts.
TABLE II
Glucose-6-phosphate dehydrogenase phenotypes found in Latin America and the Caribbean
Name Class Country References
Frequency
(%)
A- III Brazil Saldanha et al. (1969), Azevedo and Azevedo (1974), Azevêdo et al. 
(1980, 1981), Weimer et al. (1981, 1991, 1998), Franco et al. (1982), 
Conceição et al. (1987), Santos et al. (1987), Schneider et al. (1987), 
Garlipp and Ramalho (1988), Saad and Costa (1992), Bortolini et al. 
(1997), Silva et al. (2004), Santana et al. (2009), Iglessias (2009)
89.4
Costa Rica Sáenz et al. (1985, 1986), Chaves et al. (1988), Madrigal et al. (1990)
Cuba González et al. (1975), Hidalgo et al. (1987)
Ecuador Martínez-Labarga et al. (1999)
Jamaica Gibbs et al. (1972)
Mexico Lisker et al. (1966, 1969, 1981, 1988, 1990)
Suriname Geerdink et al. (1974)
Venezuela Boada and Yates (1979), Bortolini et al. (1998)
Uruguay Weimer et al. (1998)
Attica III Puerto Rico McCurdy et al. (1973) Rare
Aymara None Chile Ferrell et al. (1980) Rare
Carapicuíba II/III Brazil Barretto and Nonoyama (1991) Rare
Castilla III Mexico Lisker et al. (1977)







Lisker et al. (1978)
McCurdy et al. (1973) Rare
Cuiabá IV Brazil Barretto and Nonoyama (1987) Rare
Distrito Federal III Mexico Lisker et al. (1981)
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This systematic review led to the creation of a data-
base of G6PD mutations found in LA and the Caribbean 
(Table III). Thirty works from seven countries presented 
data on the enzyme characterisation of G6PD variants 
at the DNA level. To date, 38 G6PDd mutations have 
been reported in LA: among these, 30 (78.9%) are single 
nucleotide substitutions, seven (18.4%) are multiple mu-
tations (2 or more substitutions) and one (2.6%) is a dele-
Name Class Country References
Frequency
(%)
El Morro III Puerto Rico McCurdy et al. (1973) Rare
Farroupilha II/III Brazil Weimer et al. (1998) Rare
Guadalajara I Mexico Vaca et al. (1982) Rare
Guantánamo III Cuba Gutiérrez et al. (1987) Rare
Guaíba IV Brazil Weimer et al. (1981, 1998) Rare
Jalisco III Mexico Vaca et al. (1985) Rare
Lages III Brazil Weimer et al. (1998) Rare
Laguna III Brazil Weimer et al. (1984, 1998) Rare
La Habana III Cuba González et al. (1980) Rare
Mediterranean II Brazil Azevedo and Azevedo (1974), Azevêdo et al. (1980), Weimer et al. 
(1981, 1998), Franco et al. (1982), González-González and Calcines 
(1986), Garlipp and Ramalho (1988), Santana et al. (2009)
7.9
Costa Rica Sáenz et al. (1985, 1986), Chaves et al. (1988), Madrigal et al. (1990)
Cuba González-González and Calcines (1986), Hidalgo et al. (1987)
Mexico Lisker et al. (1976)
Venezuela Boada and Yates (1979)
Mexico City IV Mexico Lisker et al. (1972) Rare
Minas Gerais IV Brazil Azevedo and Yoshida (1969), Hutz et al. (1977), Weimer et al. (1981, 1998) Rare
Morelia IV Mexico Vaca et al. (1985) Rare
Nashville Anaheim I Brazil Weimer et al. (1998) Rare
Porto Alegre IV Brazil Hutz et al. (1977), Weimer et al. (1981, 1998) Rare
Puerto Limón I Costa Rica Elizondo et al. (1982) Rare
Puerto Rico III Puerto Rico McCurdy et al. (1973) Rare
San José III Costa Rica Castro and Snyder (1974) Rare
San Juan III Puerto Rico McCurdy et al. (1973) Rare
Santa Clara III Cuba Gonzalez et al. (1990) Rare
Santamaría II Costa Rica Sáenz et al. (1984) Rare
São Borja IV Brazil Weimer et al. (1998) Rare
São Paulo IV Brazil Barretto (1983) Rare
Seattle/Athens-like III Brazil McCurdy et al. (1973), Hutz et al. (1977), Weimer et al. (1981, 1998) 0.2
Tepic III Mexico Lisker et al. (1985)
Trinacria III Mexico Vaca et al. (1985) Rare
Varadero I Cuba Estrada et al. (1982) Rare
Villa Clara III Cuba Gonzalez et al. (1990) Rare
Tepic, Castilla, Distrito Federal phenotypes were identified as A- (202G→A, 376A→G) a posteriori according to genetic char-
acterisation (Beutler et al. 1991a). Frequency was retrieved from representative community surveys in males. A rare variant has 
a prevalence of less than 0.1%.
tion. Eleven variants were identified in class I G6PDd 
and 27 were classified in classes II or III G6PDd. Twen-
ty-three novel mutations were described in LA.
G6PD characterisation at the DNA level was per-
formed with samples collected from 13 community sur-
veys on G6PDd prevalence from only five countries. 
This scarcity of data constitutes a major limitation for 
a more reliable understanding of G6PDd epidemiology 
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in LA. Biochemical methods strongly suggested the pre-
dominance of the African variant across this continent, in 
agreement with other genotyping studies from the same 
areas, suggesting the reasonable reliability of gel electro-
phoresis as a diagnostic tool for G6PD enzyme variants.
Investigation of different PQ regimens must also in-
clude appropriate measures of tolerability and be able to 
quantify the risk of severe adverse events, especially in 
patients with deficient variants of G6PD. However, only a 
few publications have addressed the correlation between 
G6PD variants and clinical presentations in LA. Out of the 
30 articles reporting G6PDd at the DNA level (Table III), 
11 referred to reports of rare class I mutations associated 
with chronic non-spherocytic haemolytic anaemia. Anae-
mia was recorded in a case report focusing on one male 
G6PD A-202A mutation carrier (Agudelo-Flórez et al. 2004). 
Mild haemolysis was observed in a girl with both G6PD 
Sumaré (class I variant) and G6PD A- alleles (Saad & Cos-
ta 2003). One Brazilian publication presents three male as-
ymptomatic carriers of the Mediterranean, São Borja and 
Seattle mutations and one carrier of the Anaheim mutation 
with a history of NNJ, several hospitalisation episodes and 
severe anaemia (Weimer et al. 1993). None of these men-
tioned case reports involved treatment with PQ.
The severity of particular G6PD mutations and their 
prevalence in a population determine the risk of indi-
vidual (and eventually population-wide) administration 
of PQ. For example, G6PDd is common among people of 
African origin, but the enzyme deficiency is relatively 
mild (A- variant) with most having greater than 10% of 
the wild-type enzyme activity (Beutler 1991). Patients 
with the G6PD A- variant are relatively resistant to se-
rious reactions to PQ-induced haemolysis (Dern et al. 
1954); G6PD A- individuals dosed with daily PQ for four 
months have been observed to typically recover from 
relatively shallow AHA within about three weeks, de-
spite continued daily dosing (Dern et al. 1954, Alving et 
al. 1960). Some reports from LA countries are in agree-
ment with these findings. In this continent, G6PD A- is 
the predominant variant observed among hundreds of 
healthy male blood donors (Saad et al. 1997b, Compri et 
al. 2000, Hamel et al. 2002, Oliveira et al. 2009). More-
over, this variant was not a risk factor for moderate hy-
perbilirubinaemia (Mezzacappa et al. 2010) or anaemia 
(Cardoso et al. 2012) in Brazil. On the other hand, G6PD 
A- type deficiency was associated with significant hae-
moglobin drop in patients using antimalarial prepara-
tions containing dapsone in Africa (Pamba et al. 2012).
Nonetheless, these findings do not conclusively in-
dicate that non-specific administration of PQ is safe. To 
be acceptable, mass drug administration (MDA) needs 
to heavily rely on the safety of the intervention, as it will 
reach a majority of healthy individuals (Hsiang et al. 
2013, Kondrashin et al. 2014). The use of an unsafe drug 
for MDA purposes could impose serious hazards to the 
population, as there is no efficient or accurate rapid diag-
nostic test currently available. The relatively low number 
of reported cases of haemolysis from malaria endemic 
countries that prescribe PQ irrespective of G6PD status 
assessment may be due to under-diagnosis and under-
reporting of this complication, rendering the need for a 
more thorough assessment of the clinical burden of this 
condition in the region (Douglas et al. 2012). Should MDA 
be conducted with PQ in countries with a high preva-
lence of underlying G6PD deficiency, a high number of 
adverse events would be expected to occur at the commu-
nity level, in accordance with the distribution of G6PD 
variants present in this community. Albeit sporadic, the 
number of cases of severe haemolysis, haemoglobinuria, 
acute kidney injury and associated fatalities may not be 
significant, but they are not negligible. This is especially 
true in certain geographical areas in which G6PDd rates 
are high, particularly in those nations where the Medi-
terranean variant is prevalent. The G6PD Mediterranean 
variant prevails in certain ethnic groups originating in 
the Mediterranean and West Asia. Individuals with the 
G6PD Mediterranean variant have minimal G6PD activ-
ity (< 1%) and are predisposed to favism and severe life 
threatening haemolysis following PQ therapy (Beutler 
1991, Howes et al. 2013). In Panama, a mutation analysis 
revealed that a Mediterranean variant was behind the de-
velopment of kernicterus after exposure to naphthalene in 
a male patient (de Gurrola et al. 2008). In Manaus, Brazil, 
G6PDd was associated with a considerably higher risk of 
malaria-related transfusions, suggesting that G6PDd may 
contribute to a considerable proportion of malaria-related 
complications in an area with an unexpectedly high prev-
alence of the Mediterranean variant (Ramos-Júnior et al. 
2010, Lacerda et al. 2012a, Santana et al. 2013).
A recent systematic review analysed 47 cases of con-
firmed PQ-induced haemolysis in LA and the Caribbean 
(Monteiro et al. 2014). Unfortunately, none of these cases 
had genotyped for G6PD variants.
G6PDd among Amerindian populations - This sys-
tematic review analysed 24 publications regarding 
G6PDd prevalence among Amerindians belonging to 55 
ethnic groups living in 12 countries and 64 different vil-
lages. A total of 7,205 individuals were tested for G6PDd 
(2,482 males, 499 females and 4,224 individuals without 
gender information). Most of this information was gen-
erated from anthropological studies on the genetic vari-
ability of indigenous groups using the G6PD phenotype 
as one of the markers. A great interest in this area has al-
lowed the accumulation of valuable information regard-
ing G6PDd prevalence in this ethnic group.
In LA, the first work concerning G6PDd in areas of 
P. vivax circulation found no G6PDd individuals amongst 
228 Peruvian Amerindians (Best 1959). Indeed, studies 
from different areas of this continent confirmed the vir-
tual absence or a very low frequency of G6PDd in Am-
erindian populations. In this review, only eight deficient 
individuals were detected among 7,205 screened Amer-
indians. In Colombia, one Wanauna individual was found 
to be deficient (Monsalve et al. 1987) and in Mexico, 
four Amerindians were diagnosed as G6PDd (Lisker et 
al. 1966). Authors of the last two studies concluded that 
this could be explained by the introduction of genes from 
black neighbouring communities. In the Amazon, G6PDd 
was detected in one Makiritare Amerindian with approx-
imately 20% of normal G6PD enzyme activity in relation 
to average G6PD activity found in control individuals 
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from the same village (Mohrenweiser & Neel 1984). The 
geographic patterns presented here reinforce these find-
ings, with lower G6PDd frequencies observed in Mexico, 
Argentina, Bolivia and Peru and this finding may be ex-
plained by the fact that large portions of the populations 
in these countries have an Amerindian background.
In parallel with the virtual absence of G6PDd among 
Amerindian populations, the literature indicates that 
these groups of people are not susceptible to haemoly-
sis caused by oxidative stressors such as PQ and other 
drugs. A recent systematic review has shown that among 
all published cases of haemolysis triggered by various 
oxidative agents in LA, none have involved Amerindi-
ans (Monteiro et al. 2014). Reinforcing these results, in 
Nicaragua, the administration of 10-20 mg of PQ base 
during 14 days to 321 Miskito Amerindians with chronic 
malaria did not lead to any report of secondary haemo-
lysis (Thaeler Jr et al. 1953). This probable safety upon 
PQ administration in Amerindian population is of great 
value to malaria control programmes because malaria 
remains a major health problem in Amerindian villages 
across this continent.
Safety of PQ use in LA and the Caribbean - The most 
feared complication of PQ administration is triggering 
haemolysis in G6PDd individuals. PQ may also cause 
clinically non-significant haemolysis in non-G6PDd 
individuals as well. Other major side effects include 
methemoglobinaemia (MetHb), hypersensitivity reac-
tions and gastrointestinal disturbances (Hill et al. 2006). 
Because G6PDd screening prior to PQ administration is 
not usually routine practice in LA or Caribbean coun-
tries, the risk of drug-induced haemolytic episodes is 
always present. Although PQ is the only available drug 
presenting good efficacy for the treatment of both P. 
vivax and P. falciparum primary infections and relapses 
of P. vivax malaria (Baird 2011), it still presents many 
uncertainties regarding its mode of function, safety and 
tolerability (Steinhardt et al. 2011) despite having been 
extensively used for more than 60 years. Safety issues 
are most concerning in those populations considered 
most vulnerable, including pregnant women and very 
young children with uncertain G6PD status, for which 
the WHO recommends not using PQ due to scarce evi-
dence of its safety (WHO 2010).
Several reports describe haemolytic events associ-
ated with PQ use in G6PDd individuals in LA and the 
Caribbean, including El-Salvador (Bloch et al. 1970), 
Cuba (Pérez & Meléndez 1989, Menéndez-Capote et al. 
1997), Trinidad and Tobago (Chadee et al. 1996), Puerto 
Rico (McCurdy et al. 1973) and Brazil (Silva et al. 2004, 
Ramos-Júnior et al. 2010, Lacerda et al. 2012a). A large 
portion of these patients required blood replacement 
therapy, presented long-lasting haemolysis and were un-
able to complete full treatment (Monteiro et al. 2014).
The clinical impact of G6PDd is also important in 
the Brazilian Amazon, a region accounting for 99.8% of 
the registered cases of malaria in Brazil (Oliveira-Fer-
reira et al. 2010). In this region, G6PDd has been associ-
ated with an increased risk for malaria-related transfu-
sions (Santana et al. 2009, 2013) and death triggered by 
PQ-induced haemolysis (Lacerda et al. 2012a). Of note, 
the standard PQ regimen in Brazil differs from that 
recommended by the WHO. In an attempt to increase 
treatment compliance, the Brazilian Ministry of Health, 
in the mid-1990s, recommended the administration of 
30 mg/day of PQ over only seven days (Marques et al. 
2001), rather than maintaining the conventional 15 mg/
day, 14-day regimen course proposed by the WHO. The 
decrease in length of PQ treatment to seven days led to 
an increase in the drug dosage (Silva et al. 2010). The 
precise consequences of this schedule change on the risk 
of haemolysis prevalence triggered by PQ in G6PDd in-
dividuals remain to be determined.
Other adverse events, such as MetHb, may also occur 
following PQ therapy. In G6PDd patients, a significantly 
higher occurrence of MetHb was observed following oral 
therapy with PQ when compared to non-G6PDd individ-
uals (Santana et al. 2007, Ferreira et al. 2011). In Nica-
ragua, however, administration of 10-20 mg of PQ base 
daily over 14 days to 321 Miskito Indians with chronic 
malaria did not lead to any case of secondary adverse 
events (Thaeler Jr et al. 1953). LA literature is contradic-
tory in the presentation of adverse events after treatment 
with PQ. Despite one Colombian study reporting that 
two and five-fold higher PQ dosages caused only short-
term mild-to-moderate side effects (Carmona-Fonseca et 
al. 2009), another study from this same country reported 
severe gastrointestinal distress in a small proportion of 
non-immune male soldiers (Soto et al. 1999).
Most of the countries presenting cases of PQ-induced 
haemolysis present a higher prevalence of G6PDd when 
compared to other countries. Although only a few cases 
are reported in these studies, the real prevalence of clini-
cal haemolytic syndromes is unknown, most likely due 
to lack of appropriate surveillance. As most studies aim 
to study the efficacy of PQ regimens against malaria, 
safety issues are still systematically underexplored. Gaps 
still need to be filled regarding the presence of serious 
adverse events due to PQ therapy in both normal G6PD 
and deficient populations.
Some perspectives concerning rapid diagnostic tests 
in LA - Several technical and operational knowledge 
gaps must be addressed to expand access to G6PDd test-
ing and to ensure that a patient’s G6PD status is known 
before deciding to administer PQ (Domingo et al. 2013). 
A rapid and accurate diagnosis of G6PDd under field 
conditions before starting PQ treatment is currently a 
major challenge (malERA 2011, Domingo et al. 2013). 
A prerequisite to introducing G6PD testing is the avail-
ability of high-quality G6PDd tests with product profiles 
that are compatible with end-use cases. The diagnostic 
gold standard technique for detecting G6PDd is based 
on the measurement of NADPH production by the en-
zyme by means of spectrophotometry, thus requiring a 
laboratory environment, sophisticated equipment and 
experienced personnel. For screening activities in less 
complex environments, the fluorescent spot test has 
been considered the most appropriate assay, although it 
requires ultraviolet lamp, bath and micropipette. Given 
the characteristics described above, none of the currently 
available G6PDd tests can be routinely employed in field 
conditions across most malarial areas.
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In this context, in 2012, decision-makers gathered at a 
workshop held in Bangkok, Thailand and indicated that a 
rapid test for G6PDd should have characteristics similar 
to rapid tests used in malaria diagnosis: feasibility and 
ease of interpretation, stability at high temperature and 
humidity, ability to test on capillary blood, sensitivity 
and specificity higher than 95% and 75%, respectively, 
with a cut-off set at 30-40% of the median normal G6PD 
activity (Domingo et al. 2013).
Although G6PDd systematic testing is currently not 
performed in malaria endemic areas, there are two rapid 
tests to detect G6PDd in field conditions: BinaxNOW® 
G6PD, which is already being commercialised, and Car-
eStart® G6PD, which was recently developed and is now 
showing promising results (Tinley et al. 2010, Kim et 
al. 2011, von Fricken et al. 2014). The scarcity of stud-
ies on both tests may limit their use by malaria con-
trol and eradication programs because there are issues 
related to their physical and biochemical conservation 
in the field. High levels of humidity and temperature 
impact the tests’ accuracies by indirectly impairing the 
establishment of deficiency cut-off points. Better assess-
ments are required to better determine the real useful-
ness and costs of these tests in LA and Caribbean coun-
tries. BinaxNOW® G6PD must be kept between 15-30ºC 
for storage and between 18-25ºC during performance 
and this test requires venous blood for the essay, which 
may increase operating costs and hamper its use. In the 
United States of America, this test presented high ac-
curacy with 98% sensitivity and 97% specificity, when 
using a cut-off of < 4.0 U/gHb, corresponding to 49% of 
normal G6PD activity in the sample (Tinley et al. 2010). 
Regarding CareStart® G6PD, a study from Cambodia 
established sensitivity and specificity of 68% and 100%, 
respectively, at a cut-off of < 3.6 U/gHb (30% of normal 
activity), demonstrating that the test is not affected by 
high storage or execution temperatures when performed 
with samples collected by venipuncture or finger-stick 
on peripheral blood puncture (Kim et al. 2011).
A standard approach that could define absolute val-
ues of normal G6PD activity may be required to validate 
G6PDd diagnostic tests (Domingo et al. 2013). Typically, 
G6PDd has been defined as a percentage of normal G6PD 
activity. No rapid test for G6PD has been assessed in LA 
malaria endemic epidemiological conditions. In this re-
view of LA and Caribbean studies, a lack of standardisa-
tion was noticed in the attempts both to assess normal 
G6PD activity as well as to define a cut-off for G6PDd 
diagnosis. Twenty-five community surveys estimated 
G6PDd prevalence by quantitative methods but, unfortu-
nately, the majority of the studies used inconsistent defi-
nitions of normal G6PD activity though different G6PD 
cut-off points or degrees of G6PDd. Some studies fol-
lowed manufacturer’s definitions of normal activity and 
G6PDd. Ambiguity in the method of calculation presents 
practical difficulties in deploying G6PD tests in routine 
care in LA and Caribbean countries. This ambiguity in 
interpreting results is particularly problematic in qualita-
tive tests, which highlights that an accurate evaluation of 
rapid tests is urgently needed in these countries.
From a public health perspective, uncertainty remains 
in whether G6PD testing deficiency status needs to be 
taken into account for PQ-based radical cure in some 
populations, as reflected in the current WHO guide-
lines. However, from a patient management perspective, 
where the individual risk/benefit ratio dictates optimal 
treatment, knowing the G6PD status of the patient is a 
prerequisite for prescribing an 8-aminoquinoline-based 
drug (Domingo et al. 2013). Given the scarcity of rapid 
test evaluations, it becomes a priority to study the use 
these tests in the diagnosis of G6PD deficiency in tropi-
cal areas where malaria is endemic, especially regarding 
their accuracy. These data are as essential for economic 
evaluation as for their incorporation by health services. 
After extensive studies of accuracy, the cost-effective-
ness and budget impact of incorporating G6PDd diag-
nosis in the standard of care for malaria will need to be 
assessed to support decision-making steps.
A cost-effectiveness analysis is currently the method 
most commonly used for economic evaluation in health 
care and in the field of health technology assessment. 
Such an approach systematically compares costs and 
consequences of health interventions for prevention, di-
agnosis or treatment from among the options that have 
a common purpose (Haddix et al. 2003). The evidence 
about the cost-effectiveness of interventions is gener-
ally used to instruct decisions regarding the allocation 
of funds from the public sector, helping to identify in-
terventions that represent the best use of resources. In 
addition to cost-effectiveness analyses, the evaluation of 
the budget impact can aid decision making by providing 
financial forecasts if the technology in question is ad-
opted by national health systems (Ribeiro et al. 2012).
Rapid tests have the potential to change radically the 
healthcare process for patients presenting G6PDd, poten-
tially also allowing the optimisation of available financial 
resources because deficiency diagnosis likely decreases 
other costs such as those related to hospitalisations. It is 
necessary, however, to compare such costs and benefits 
to those related to possible relapses from P. vivax infec-
tions and thus determine the importance of G6PDd de-
tection among individuals infected with P. vivax through 
an effective and economically viable rapid test. It is also 
important to consider a local research agenda in LA to 
regionally assess the cost and accuracy of rapid tests in 
field conditions. If rapid tests prove effective in field con-
ditions, studies of cost-effectiveness and budget impact 
for health services are recommended to support the in-
corporation of these tests into control programs aimed at 
malaria elimination in the Western Hemisphere.
Concluding remarks - Malaria elimination will be 
possible only with serious regional and international 
efforts addressing asymptomatic infection and persis-
tent P. vivax infection. Currently available drugs that 
can radically cure P. vivax malaria and are able to re-
duce transmission of malaria parasites are those in the 
8-aminoquinoline family, such as PQ. Tafenoquine, 
which is also an 8-aminoquinoline, is currently being 
assessed as a single-dose radical cure therapy and may 
represent a significant advance in P. vivax therapy. Un-
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fortunately, individuals carrying the G6PDd trait are at 
risk to develop severe haemolysis if exposed to any of 
these drugs, implying that radical cure regimens will re-
quire broader testing for G6PD deficiency.
In conclusion, (i) low prevalence rates of G6PDd 
were recorded in Argentina, Bolivia, Mexico, Peru 
and Uruguay. Studies performed in Curaçao, Ecuador, 
Jamaica, Saint Lucia, Suriname and Trinidad, as well 
as some surveys carried out in areas of Brazil, Colom-
bia and Cuba showed high prevalence rates (> 10%) of 
G6PDd, (ii) G6PD encoded by the G6PD A-202A muta-
tion is the most broadly distributed genotype across LA, 
identified in 81.1% of deficient individuals surveyed in 
the continent, (iii) G6PDd seems to be virtually absent 
among Amerindians, suggesting that PQ use is safe in 
these populations and (iv) rapid and accurate diagnosis 
of G6PDd under field conditions remains a major chal-
lenge in LA. The development of a rapid G6PD diagnos-
tic test could help in reducing unnecessary exposure to 
drugs capable of inducing haemolysis, such as PQ, be-
cause LA faces a scarcity of clinical and epidemiologi-
cal information concerning this enzyme’s activity in the 
population. The development of newer and inexpensive 
methods for field-testing of G6PD deficiency should go 
hand in hand with studies of PQ and tafenoquine effec-
tiveness. Reliable exclusion of patients at risk of severe 
harm opens the possibility for safer and more effective 
deployment of high dose regimens. If the elimination of 
P. vivax is to be achieved, a coordinated effort will be 
necessary to provide evidence across the spectrum of P. 
vivax endemic regions and to deploy a safe anti-relapse 
therapy regimen in an effective manner.
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